Canadian researchers developed a tool to use with low-dose CT screening that accurately estimates the probability of lung nodule malignancies.
Predictive tools can be used to accurately estimate the probability of malignancy in lung nodules detected by low-dose screening CT scans, according to a study published in the New England Journal of Medicine.
Low-dose CT screening reduces mortality from lung cancer by 20 percent. However, the screening also discovers more nodules that require further investigation, which could include invasive diagnostic procedures, with its associated risks of complications.
Using a population-based prospective study, Canadian researchers investigated factors that could predict the probability that these lung nodules would be malignant. Such predictions could reduce the risk of morbidity and mortality from such screening programs.
Two cohorts were analyzed: a development data set comprising 1,871 patients who participated in the Pan-Canadian Early Detection of Lung Cancer Study (PanCan) and a validation set comprising 1,090 participants from British Columbia Agency (BCCA) chemoprevention trials, which were sponsored by the U.S. National Cancer Institute. Final outcomes were nodules of any size detected by baseline low-dose CT scans. Determinants included nodule size, density, and location, previous diagnosis, family history, and demographic information (age and sex of patient).
Participants had at least one non-calcified lung nodule on the baseline low-dose CT scan. Follow-ups with repeat low-dose CT were done at three to 12-month intervals. This follow-up continued until:
·Nodules were considered to be stable for at least two years;
·Development of benign calcification;
·Nodules were no longer visible;
·Biopsy or surgical resection determined that nodules were malignant or benign.
The researchers found 7,008 nodules (102 malignancies) among the PanCan group and 5,021 (42 malignancies) in the BCCA group, for a cancer rate of 5.5 percent and 3.7 percent, respectively. Nodules in the upper lobes had a higher probability of malignancy.
“Predictive tools based on patient and nodule characteristics can be used to accurately estimate the probability that lung nodules detected on baseline screening low-dose CT scans are malignant,” the researchers concluded.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.